New Training for RefluxStop® Procedures by Leading Surgeon in the U.S. Marks a Major Step for Innovative GERD Treatment
Introduction
In a significant step for gastroesophageal reflux disease (GERD) treatment in the United States, Dr. John C. Lipham, an esteemed Professor of Surgery at the University of Southern California (USC), has commenced his training on RefluxStop® surgical procedures in Mainz, Germany. This initiative is not just a key milestone for Dr. Lipham but also highlights the increasing demand for advanced anti-reflux solutions following the FDA's recent approval of the RefluxStop device.
The Technology Behind RefluxStop®
RefluxStop® stands out as a groundbreaking device designed to restore the anti-reflux barrier without the complications associated with traditional surgical methods. The technology eliminates the need for tightening the esophagus, which often leads to uncomfortable side effects such as swallowing difficulties, gas, and bloating. Dr. Lipham noted, "The need for effective treatment options is vast, and many patients are seeking alternatives due to the limitations of their current therapies."
Training and Procedures
During his week in Germany, Dr. Lipham observed procedures conducted by noted surgeon Dr. Moustafa Elshafei at Marienhaus Klinikum Mainz. These training sessions will be essential as he prepares to introduce RefluxStop to his patients back in Los Angeles. He added, "I’m eager to begin treating my patients with this innovative solution that has already demonstrated positive outcomes in over 1,800 cases across Europe."
Future Prospects
The expectation for RefluxStop in the U.S. market is amplified by the planned arrival of several additional U.S. surgeons who are scheduled to undergo similar training by mid-November. Dr. Peter Forsell, Founder and CEO of Implantica, expressed his enthusiasm regarding the upcoming expansion, stating, "Our European results have laid the groundwork for our entry into the U.S. market. With FDA approval secured and additional surgeons preparing for training, we are ready to reshape the future of GERD treatment in the U.S."
The Demand for Innovative Solutions
A staggering 78 million Americans suffer from acid reflux, with over 40% continuing to experience symptoms despite adherence to daily medications. The introduction of the RefluxStop device, which has been well-received across Europe, is a response to this unmet need, providing a feasible alternative for many patients who have been underserved by conventional methods.
Conclusion
As the RefluxStop team prepares for its official U.S. launch, the excitement surrounding this innovative solution continues to grow. The integration of such technology could revolutionize the approach to treating GERD, offering relief to numerous individuals grappling with this condition. Through enhanced training and experienced surgeons, Implantica is poised to make a significant impact on the landscape of anti-reflux surgery, advancing patient care into a new era.
References
1. Delshad, S.D., et al., Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 2020. 158(5) p. 1250-1261.
2. Becker, V, et al. Clinical trial persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007. 26 p.1355-1360.
In a significant step for gastroesophageal reflux disease (GERD) treatment in the United States, Dr. John C. Lipham, an esteemed Professor of Surgery at the University of Southern California (USC), has commenced his training on RefluxStop® surgical procedures in Mainz, Germany. This initiative is not just a key milestone for Dr. Lipham but also highlights the increasing demand for advanced anti-reflux solutions following the FDA's recent approval of the RefluxStop device.
The Technology Behind RefluxStop®
RefluxStop® stands out as a groundbreaking device designed to restore the anti-reflux barrier without the complications associated with traditional surgical methods. The technology eliminates the need for tightening the esophagus, which often leads to uncomfortable side effects such as swallowing difficulties, gas, and bloating. Dr. Lipham noted, "The need for effective treatment options is vast, and many patients are seeking alternatives due to the limitations of their current therapies."
Training and Procedures
During his week in Germany, Dr. Lipham observed procedures conducted by noted surgeon Dr. Moustafa Elshafei at Marienhaus Klinikum Mainz. These training sessions will be essential as he prepares to introduce RefluxStop to his patients back in Los Angeles. He added, "I’m eager to begin treating my patients with this innovative solution that has already demonstrated positive outcomes in over 1,800 cases across Europe."
Future Prospects
The expectation for RefluxStop in the U.S. market is amplified by the planned arrival of several additional U.S. surgeons who are scheduled to undergo similar training by mid-November. Dr. Peter Forsell, Founder and CEO of Implantica, expressed his enthusiasm regarding the upcoming expansion, stating, "Our European results have laid the groundwork for our entry into the U.S. market. With FDA approval secured and additional surgeons preparing for training, we are ready to reshape the future of GERD treatment in the U.S."
The Demand for Innovative Solutions
A staggering 78 million Americans suffer from acid reflux, with over 40% continuing to experience symptoms despite adherence to daily medications. The introduction of the RefluxStop device, which has been well-received across Europe, is a response to this unmet need, providing a feasible alternative for many patients who have been underserved by conventional methods.
Conclusion
As the RefluxStop team prepares for its official U.S. launch, the excitement surrounding this innovative solution continues to grow. The integration of such technology could revolutionize the approach to treating GERD, offering relief to numerous individuals grappling with this condition. Through enhanced training and experienced surgeons, Implantica is poised to make a significant impact on the landscape of anti-reflux surgery, advancing patient care into a new era.
References
1. Delshad, S.D., et al., Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 2020. 158(5) p. 1250-1261.
2. Becker, V, et al. Clinical trial persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors - a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther. 2007. 26 p.1355-1360.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.